A trichloroethane solvent review should not wait for a final TSCA risk-management rule. EPA’s draft risk evaluation for 1,1,2-trichloroethane gives buyers a reason to check current approvals, intended uses, supplier documentation, and substitution plans before the regulatory path becomes more restrictive.
For product selection teams, the question is no longer just whether the solvent works. It is whether the material still deserves a place on the approved list beside documented use conditions, current SDS information, and alternatives that may need qualification under the same discipline used for chemical grade selection.
Draft Risk Findings Should Trigger Internal Review
EPA released its draft risk evaluation for 1,1,2-trichloroethane on July 24, 2026. The agency stated that the draft identifies significant contributions to unreasonable risk to workers from dermal and inhalation exposure across 10 occupational conditions of use in its draft risk evaluation release.
That is not the same as a final restriction. It is also not something buyers should ignore until the rulemaking process ends.
A draft risk evaluation signals where EPA is focusing the risk record. If a facility buys or specifies the chemical, procurement should identify where it is used, who requested it, whether a current SDS is on file, and whether any supplier or customer approvals depend on the material.
The risk is approval inertia. A product remains active because no one has removed it, not because anyone has recently confirmed that it remains appropriate.
Trichloroethane Solvent Review Starts With the Approved List
The approved-material list should be the first place to look. If 1,1,2-trichloroethane appears as an active product, substitute, laboratory chemical, processing aid, cleaning material, or component in a supplier blend, the file should be reviewed.
The buyer should not assume every solvent name reveals the substance clearly. Supplier trade names, blend names, and legacy product codes can hide the identity until the SDS or composition statement is checked.
A practical review should identify the product name, supplier, CAS number, concentration where relevant, use location, responsible department, annual quantity, and reason for approval.
The review should also separate active use from inactive availability. A chemical may no longer be used routinely but remain orderable in the ERP system. That creates a reentry path if an employee searches an old product code.
Exposure Pathways Should Shape Substitution Timing
EPA’s current 1,1,2-trichloroethane risk-evaluation page describes the chemical as undergoing TSCA risk evaluation and identifies the broader review context for hazards, exposures, conditions of use, and potentially exposed or susceptible populations in its chemical risk evaluation file.
Buyers should translate that into a site question: which use conditions create the greatest approval concern?
A small laboratory reference use is not the same as repeated cleaning, open transfer, formulation, or maintenance use. A closed system is not the same as manual application. An on-site use is not the same as a product shipped downstream.
Those distinctions affect substitution timing. A high-exposure, non-critical use may deserve faster replacement planning. A technically specialized use may require longer testing, customer approval, or engineering review.
Approval Controls Should Prevent Automatic Reorders
Once the exposure concern is tied to a specific use, the purchasing system should reflect that risk. A solvent under review should not remain available to every department through the same routine reorder process used for low-concern materials.
The approved-material record should identify who may request the solvent, which process or location is authorized, what quantity limits apply, and when EHS or technical review is required before another purchase. That prevents a legacy product code from becoming an uncontrolled route back into the plant.
Procurement should also flag alternate suppliers and substitute products for the same review. A replacement trade name may still contain the same substance or create a similar exposure concern if composition and use conditions are not checked.
The objective is controlled continuity. Buyers can preserve needed operations while ensuring that every reorder reflects the current risk review, not an old approval that no longer matches the regulatory direction.
Product Selection Needs a Documented Decision Table
The following table helps buyers decide whether a solvent should remain approved, be restricted internally, or move into substitution review.
| Review factor | Buyer question | Possible action |
|---|---|---|
| Product identity | Does the SDS confirm 1,1,2-trichloroethane content? | Confirm, relabel, or block unclear items |
| Use condition | Which department uses it and for what task? | Approve only defined applications |
| Exposure route | Could inhalation or dermal exposure occur? | Route to EHS for review |
| Process importance | Is the solvent critical to quality or output? | Prioritize testing if substitution is needed |
| Supplier support | Can the supplier provide current documents and notices? | Update or replace supplier file |
| Alternative status | Are substitutes technically qualified? | Start controlled trials |
| ERP control | Can unauthorized reorders occur? | Restrict product code access |
The table should not be treated as a regulatory determination. It is a purchasing decision tool that forces the right questions before a reorder becomes automatic.
Substitution Should Not Be a Simple Product Swap
Replacing one chlorinated solvent with another material can create new technical and regulatory issues. A candidate may change residue, drying behavior, equipment impact, emissions profile, waste stream, worker exposure, customer approval, or product performance.
That is why substitution should be controlled through trial design, technical acceptance criteria, supplier qualification, SDS review, and EHS assessment.
A TDS can indicate expected performance, but it does not prove that the substitute works in the buyer’s equipment. A CoA confirms batch parameters, but it does not prove long-term process suitability. A supplier declaration may address one regulatory issue while leaving other restrictions unreviewed.
The strongest approach is measured substitution, where technical performance and risk reduction are both documented.
FAQ’s
Is EPA’s draft risk evaluation a final ban?
No. A draft risk evaluation is not a final restriction. It identifies EPA’s preliminary risk findings and supports further review, comment, and later risk-management decisions.
Should buyers remove 1,1,2-trichloroethane immediately?
Not automatically. Buyers should identify current uses, verify documents, involve EHS and technical teams, restrict uncontrolled reorders, and begin substitution planning where the use profile justifies it.
What is the first document to check?
Start with the current supplier SDS to confirm chemical identity and composition. Then compare it against the approved-material list, purchase history, process use, and internal authorization.
Trichloroethane Solvent Review Should Stay Ahead of Rulemaking
A trichloroethane solvent review gives buyers time to act before final requirements create a compressed decision window. That review should identify active uses, remove inactive purchasing routes, document exposure assumptions, and prioritize alternatives where needed.
The next signal to monitor will be EPA movement from risk evaluation toward risk management. Waiting until then may leave procurement with fewer qualified suppliers, shorter trial timelines, and more pressure to approve a substitute too quickly.
Product selection is strongest when it is proactive. If a solvent is under serious regulatory review, the approved list should show why it is still needed, where it is used, and what the organization will do if continued use becomes harder to defend.